JP2025508050A5 - - Google Patents
Info
- Publication number
- JP2025508050A5 JP2025508050A5 JP2024553353A JP2024553353A JP2025508050A5 JP 2025508050 A5 JP2025508050 A5 JP 2025508050A5 JP 2024553353 A JP2024553353 A JP 2024553353A JP 2024553353 A JP2024553353 A JP 2024553353A JP 2025508050 A5 JP2025508050 A5 JP 2025508050A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- acid sequence
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263268967P | 2022-03-07 | 2022-03-07 | |
| US63/268,967 | 2022-03-07 | ||
| PCT/US2023/063795 WO2023172879A2 (en) | 2022-03-07 | 2023-03-06 | Multiplex gene edited cells for cd70-directed cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508050A JP2025508050A (ja) | 2025-03-21 |
| JP2025508050A5 true JP2025508050A5 (https=) | 2026-03-12 |
Family
ID=87935884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553353A Pending JP2025508050A (ja) | 2022-03-07 | 2023-03-06 | Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230390392A1 (https=) |
| EP (1) | EP4482872A4 (https=) |
| JP (1) | JP2025508050A (https=) |
| AU (1) | AU2023232083A1 (https=) |
| CA (1) | CA3254363A1 (https=) |
| WO (1) | WO2023172879A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| AU2021286655A1 (en) | 2020-06-12 | 2023-01-05 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
| CN117844811A (zh) * | 2024-03-08 | 2024-04-09 | 上海恒润达生生物科技股份有限公司 | 靶向敲除CD70基因的sgRNA组合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030022311A1 (en) * | 1996-05-21 | 2003-01-30 | Dunnington Damien D. | Human CIS protein |
| US20050271660A1 (en) * | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| JP5122441B2 (ja) * | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス， インコーポレイテッド | ヒト化抗ｃｄ７０結合剤およびその使用 |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US11166985B2 (en) * | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| EP3707258A1 (en) * | 2017-11-06 | 2020-09-16 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy |
| EP3788369A1 (en) * | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| MX2020012028A (es) * | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| WO2021095010A1 (en) * | 2019-11-13 | 2021-05-20 | Crispr Therapeutics Ag | Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70 |
| JP2023502780A (ja) * | 2019-11-25 | 2023-01-25 | ケーエスキュー セラピューティクス， インコーポレイテッド | 腫瘍浸潤リンパ球の活性化及び増殖方法 |
| WO2021157601A1 (ja) * | 2020-02-03 | 2021-08-12 | 国立大学法人東海国立大学機構 | がんを有する対象においてがんを処置することに用いるための抗ｍｅｆｌｉｎ抗体、および当該抗体を含む医薬組成物 |
| AU2021286655A1 (en) * | 2020-06-12 | 2023-01-05 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
| KR20230041819A (ko) * | 2020-07-29 | 2023-03-24 | 얀센 바이오테크 인코포레이티드 | Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도 |
-
2023
- 2023-03-06 JP JP2024553353A patent/JP2025508050A/ja active Pending
- 2023-03-06 AU AU2023232083A patent/AU2023232083A1/en active Pending
- 2023-03-06 EP EP23767591.3A patent/EP4482872A4/en active Pending
- 2023-03-06 US US18/179,201 patent/US20230390392A1/en active Pending
- 2023-03-06 WO PCT/US2023/063795 patent/WO2023172879A2/en not_active Ceased
- 2023-03-06 CA CA3254363A patent/CA3254363A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508050A5 (https=) | ||
| KR102777002B1 (ko) | 항글리피칸-3 항체 및 이의 응용 | |
| JP7595696B2 (ja) | Ｃｄ３抗原結合性断片及びその使用 | |
| RU2748281C2 (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| AU2020202667A1 (en) | Cd20 binding molecules and uses thereof | |
| IL258491B2 (en) | Preparations and methods for inhibiting antigens of a particular lineage | |
| KR102086656B1 (ko) | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 | |
| EP4039705A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| JP2010509931A5 (https=) | ||
| JP2021511811A5 (https=) | ||
| JP2020530306A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| HRP20110187T1 (hr) | Multispecifične deimunizirane tvari koje vežu cd3 | |
| WO2022222910A1 (zh) | 靶向gprc5d的抗体及其用途 | |
| WO2018156735A1 (en) | Bispecific antibody for cancer immunotherapy | |
| JPWO2015146437A1 (ja) | 高機能性ＩｇＧ２型二重特異性抗体 | |
| WO2004085474A2 (en) | Method of producing an antibody to epidermal growth factor receptor | |
| CN112955472A (zh) | 抗ptk7免疫细胞癌症疗法 | |
| CN111620951B (zh) | EGFP-Wnt2融合蛋白抗原和Wnt2单克隆抗体以及Wnt2单克隆抗体的应用 | |
| US20220275081A1 (en) | Binding molecule specific for lrig-1 protein and use thereof | |
| CN117858906A (zh) | 与cldn18.2和cd3结合的双特异性结合剂 | |
| JP2023508674A5 (https=) | ||
| KR20240046224A (ko) | 이중특이성 항체 및 그 용도 | |
| CN101831434B (zh) | 抗人cd45ra鼠免疫球蛋白可变区基因及用途 | |
| JP2023541456A5 (https=) |